and chronic obstructive pulmonary disease (COPD). These conditions can compromise the immune system, making it harder to ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.

Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine ... as chronic obstructive pulmonary disease (COPD ...

GSK RSV Shot 43% Effective Against Severe Disease in Third Year GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was ... to Worse Outcomes in Pulmonary Embolism Location ...

GSK’s RSV vaccine is the only RSV vaccine with efficacy ... recommending bodies determine future revaccination schedules AREXVY is the world’s first RSV vaccine and was approved based on ...

An all-encompassing guide to understanding vaccines. CDC Recommends People Ages 50 to 64 Get Pneumococcal VaccinesThe CDC now says everyone 50 to 64 years old should get a pneumococcal vaccine to ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

More African Countries Set to Approve Malaria Shot African countries are lining up to approve a new vaccine for malaria, with 20 million doses available for them to buy this year. Reuters Health ...

AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical ...